---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000143"
form_type: "8-K"
ticker: "CDT"
cik: "0001896212"
company_name: "CDT Equity Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:51:02.535706+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CDT enters consulting pacts with Thesprogen and NJS; issues 213,288 shares for $305k in services

## Summary
- Thesprogen will evaluate AZD1656 pre-clinical data and optimize development strategies; 6-month term, $155k fee paid in 108,392 shares.
- NJS to identify out-licensing partners for solid-form patent portfolio; $150k retainer in 104,896 shares plus 8% commission on transactions.
- Shares issued in unregistered transaction under Regulation D; no registration rights granted.
- Press release highlights NJS engagement to accelerate licensing and royalty-based deals for solid-form assets.

## SEC filing metadata
- accession: 0001493152-26-000143
- form_type: 8-K
- ticker: CDT
- cik: 0001896212
- company_name: CDT Equity Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1896212/000149315226000143/0001493152-26-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1896212/000149315226000143/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000143
- JSON: https://secwatch.observer/filing/0001493152-26-000143.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000143.txt

## Source-grounded claims
- claim_id: 65c7ef4361a483c545ae93fb9f368e593635e29b
  claim: CDT Equity Inc. entered into Thesprogen Agreement with Thesprogen, PC valued at $155,000 of consideration (effective 2025-12-28).
  evidence_excerpt: On December 28, 2025, CDT Equity, Inc. (the “Company” or “CDT”) and Thesprogen, PC (“Thesprogen”) entered into a Consulting Agreement (the “Thesprogen Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1896212/000149315226000143/0001493152-26-000143-index.htm
- claim_id: 7967154b808bcc100b3e113e029d19154f2a3b80
  claim: CDT Equity Inc. entered into NJS Agreement with NJS Foresight Bio-Advisory, LLC valued at one-time fixed retainer of $150,000 (effective 2025-12-29).
  evidence_excerpt: On December 29, 2025 (the “Effective Date”) the Company and NJS Foresight Bio-Advisory, LLC (“NJS”) entered into a Consulting Agreement (the “NJS Agreement,” together with the Thesprogen Agreement, the “Agreements”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1896212/000149315226000143/0001493152-26-000143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.